Rebecca M Saracino1, Devika R Jutagir1, Amy Cunningham1, Kelly A Foran-Tuller1, Mary A Driscoll1, William H Sledge1, Sukru H Emre2, Dwain C Fehon3. 1. Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut, USA. 2. Department of Surgery, Yale School of Medicine, New Haven, Connecticut, USA; Yale-New Haven Transplantation Center, New Haven, Connecticut, USA. 3. Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut, USA; Yale-New Haven Transplantation Center, New Haven, Connecticut, USA. Electronic address: dwain.fehon@yale.edu.
Abstract
CONTEXT: The prevalence of psychiatric disorders and mental health service utilization among patients with end-stage liver disease awaiting transplant remains understudied. OBJECTIVES: This study assessed the prevalence of psychological disorders and symptoms with the use of a structured diagnostic interview and self-report measures, and examined patient-reported mental health service utilization and barriers to care. METHODS: Waitlisted liver transplant candidates (N = 120) completed assessments during routine clinic appointments at a single time point. RESULTS: Participants endorsed moderate-to-severe levels of depression (19.2%), anxiety (26.7%), and Post Traumatic Stress Disorder (PTSD) (23.3%). Forty-three percent had received some form of mental health treatment in the recent past, and a range of barriers to accessing mental health services were endorsed. In a subset of 39 participants who received a structure diagnostic assessment, there was a high prevalence of current (51.3%) and past (82.1%) psychiatric disorders. Elevated scores on depression, anxiety, and PTSD measures were associated with significant decrements in health-related quality of life, but were not differentially associated with mental health service utilization. CONCLUSION: There are a significant number of end-stage liver disease patients who could benefit from intervention who are not currently connected to treatment. Many patients do not see the need for accessing services, perhaps because of a lack of insight or knowledge about the benefits of mental health treatment. Future research should determine optimal treatment and service delivery methods for this vulnerable population.
CONTEXT: The prevalence of psychiatric disorders and mental health service utilization among patients with end-stage liver disease awaiting transplant remains understudied. OBJECTIVES: This study assessed the prevalence of psychological disorders and symptoms with the use of a structured diagnostic interview and self-report measures, and examined patient-reported mental health service utilization and barriers to care. METHODS: Waitlisted liver transplant candidates (N = 120) completed assessments during routine clinic appointments at a single time point. RESULTS:Participants endorsed moderate-to-severe levels of depression (19.2%), anxiety (26.7%), and Post Traumatic Stress Disorder (PTSD) (23.3%). Forty-three percent had received some form of mental health treatment in the recent past, and a range of barriers to accessing mental health services were endorsed. In a subset of 39 participants who received a structure diagnostic assessment, there was a high prevalence of current (51.3%) and past (82.1%) psychiatric disorders. Elevated scores on depression, anxiety, and PTSD measures were associated with significant decrements in health-related quality of life, but were not differentially associated with mental health service utilization. CONCLUSION: There are a significant number of end-stage liver diseasepatients who could benefit from intervention who are not currently connected to treatment. Many patients do not see the need for accessing services, perhaps because of a lack of insight or knowledge about the benefits of mental health treatment. Future research should determine optimal treatment and service delivery methods for this vulnerable population.
Authors: Emmanuelle Corruble; Antoine Durrbach; Bernard Charpentier; Philippe Lang; Sharareh Amidi; Anne Dezamis; Caroline Barry; Bruno Falissard Journal: Behav Med Date: 2010 Jan-Mar Impact factor: 3.104
Authors: G R Santos; I F S F Boin; M I W Pereira; T C M P Bonato; R C M A Silva; R S B Stucchi; R F da Silva Journal: Transplant Proc Date: 2010-03 Impact factor: 1.066
Authors: Alok Madan; Kelly S Barth; Wendy E Balliet; Melba A Hernandez-Tejada; Jeffrey J Borckardt; Robert Malcolm; Ira Willner; David Koch; Adrian Reuben Journal: Prog Transplant Date: 2012-12 Impact factor: 1.187
Authors: Fasiha Kanwal; Ian M Gralnek; Ron D Hays; Angelique Zeringue; Francisco Durazo; Steven B Han; Sammy Saab; Roger Bolus; Brennan M R Spiegel Journal: Clin Gastroenterol Hepatol Date: 2009-03-21 Impact factor: 11.382
Authors: Aanand D Naik; Jennifer Arney; Jack A Clark; Lindsey A Martin; Anne M Walling; Autumn Stevenson; Donna Smith; Steven M Asch; Fasiha Kanwal Journal: Clin Gastroenterol Hepatol Date: 2019-07-26 Impact factor: 13.576